1. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson’s disease. Ann Neurol. 2004;55:761-765. [PubMed]

2. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology. 2007; 69:1701-1711. [PubMed]

3. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatment in development for PD. Lancet. 2008;7;927-938. [PubMed]

4. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235-245. [PubMed]

5. Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005; 128:1314-1322. [PubMed]

6. Eli Lilly. Study on the tolerability of duloxetine in depressed patients with Parkinson’s disease. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00437125. Accessed February 17, 2009.

7. Richard I. Study of antidepressants in PD (SAD-PD). Available at: http://www.clinicaltrials.gov/ct2/show/NCT000861. Accessed February 6, 2009.

8. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850-857. [PubMed]

9. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005; 4:605-610. [PubMed]

10. Jankovic J, Aguilar L G. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat. 2008;4:743-757. [PubMed]

11. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-369. [PubMed]

12. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002. [PubMed]

13. Revell S, Freidman J, Mills R, et al. A double-blind, placebo controlled, dose-escalation trial of pimavanserin in Parkinson’s disease and psychosis [abstract]. Neurology. 2008;70(suppl 1):A284.

14. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844. [PubMed]

15. Davie CA. Review of Parkinson’s disease. Br Med Bull. 2008;86:109-127. [PubMed]

16. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21:1899-1907. [PubMed]

17. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3:211-225. [PubMed]

18. Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31:577-585. [PubMed]

19. Merck Serono’s safinamide significantly improved motor function in patients with advanced Parkinson’s disease in a phase III pivotal trial [news release] Medical News Today. February 4, 2009. Available at: http://www.medicalnewstoday.com/articles/137727.php. Accessed February 17, 2009.

20. Weintraub D. Dopamine and impulse control in PD. Ann Neurol. 2008;64:S93-S100. [PubMed]

21. Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res. 2005;15:76-82. [PubMed]

22. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2003;2:107-109.

23. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord. 2005;20:680-686. [PubMed]

24. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov Disord. 2006;21:115-116. [PubMed]

25. Simuni T, Sethi K. Nonmotor manifestations of PD. Ann Neurol. 2008; 64:S65-S80. [PubMed]

26. Staskin DR. Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am. 2006;33:465-473. [PubMed]

27. Farooq MU, Naravetla B, Moore PW, Majid A, Gupta R, Kassab MY. Role of sildenafil in neurological disorders. Clin Neuropharmacol. 2008;31:353-362. [PubMed]

28. Mehta SH, Morgan JC, Sethi K. Sleep disorders associated with PD: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectr. 2008;13(suppl 4):6-11. [PubMed]

29. Porter B, Macfarlane R, Walker R. Frequency and nature of sleep disorders in a community-based population of patients with PD. Eur J Neurol. 2008;15:50-54. [PubMed]

30. Comella CL. Sleep disorders in Parkinson’s disease: an overview. Mov Disord. 2007;22(suppl 17):S367-S373. [PubMed]